AG
VIVO

Aperio Group’s Meridian Bioscience Inc VIVO Stock Holding History

Aperio Group’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$575K Buy
30,763
+784
+3% +$14.6K ﹤0.01% 1898
2020
Q3 		$509K Buy
29,979
+446
+2% +$8.67K ﹤0.01% 1803
2020
Q2 		$688K Buy
29,533
+595
+2% +$8.62K ﹤0.01% 1603
2020
Q1 		$243K Sell
28,938
-2,920
-9% -$24.6K ﹤0.01% 2014
2019
Q4 		$312K Buy
31,858
+7,263
+30% +$68.2K ﹤0.01% 2049
2019
Q3 		$234K Sell
24,595
-10,004
-29% -$105K ﹤0.01% 2121
2019
Q2 		$411K Sell
34,599
-12,999
-27% -$157K ﹤0.01% 1888
2019
Q1 		$838K Buy
47,598
+1,076
+2% +$17.9K ﹤0.01% 1452
2018
Q4 		$807K Buy
46,522
+5,653
+14% +$96.4K ﹤0.01% 1424
2018
Q3 		$609K Sell
40,869
-2,096
-5% -$32.5K ﹤0.01% 1667
2018
Q2 		$683K Sell
42,965
-8,504
-17% -$127K ﹤0.01% 1596
2018
Q1 		$731K Buy
51,469
+6,819
+15% +$101K ﹤0.01% 1497
2017
Q4 		$626K Sell
44,650
-3,252
-7% -$47.6K ﹤0.01% 1597
2017
Q3 		$685K Sell
47,902
-3,483
-7% -$49.8K ﹤0.01% 1500
2017
Q2 		$809K Buy
51,385
+14,682
+40% +$212K 0.01% 1352
2017
Q1 		$506K Buy
36,703
+22,560
+160% +$315K ﹤0.01% 1537
2016
Q4 		$250K Sell
14,143
-1,666
-11% -$29.3K ﹤0.01% 1883
2016
Q3 		$305K Buy
15,809
+2,602
+20% +$50.9K ﹤0.01% 1701
2016
Q2 		$258K Sell
13,207
-2,735
-17% -$53.6K ﹤0.01% 1728
2016
Q1 		$329K Buy
15,942
+2,986
+23% +$58.8K ﹤0.01% 1601
2015
Q4 		$266K Sell
12,956
-748
-5% -$14.3K ﹤0.01% 1685
2015
Q3 		$234K Buy
13,704
+1,528
+13% +$27.9K ﹤0.01% 1690
2015
Q2 		$227K Sell
12,176
-536
-4% -$9.94K ﹤0.01% 1789
2015
Q1 		$243K Buy
+12,712
New +$235K ﹤0.01% 1700

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aperio Group's VIVO Position: Q4 2020 in Review

Aperio Group increased its Meridian Bioscience Inc (VIVO) stake by 2.6% in Q4 2020, buying an estimated $14.6K and bringing the position to 30,763 shares worth $575K. The position accounts for ﹤0.01% of the portfolio, ranked #1898.

Aperio Group first reported a position in VIVO in Q1 2015 and has held it in 24 quarters since. The position peaked at $838K in Q1 2019. 192 funds tracked by Wall St. Rank hold VIVO as of Q4 2020.

  • Aperio Group held 30,763 shares of Meridian Bioscience Inc worth $575K as of Q4 2020.
  • Aperio Group bought 784 Meridian Bioscience Inc shares in Q4 2020, an estimated $14.6K.
  • Meridian Bioscience Inc made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1898 holding.
  • Aperio Group first reported a position in Meridian Bioscience Inc in Q1 2015 and has held it in 24 quarters since.
  • Aperio Group's Meridian Bioscience Inc position peaked at $838K in Q1 2019.
  • 192 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.